Search results
Showing 751 to 800 of 874 results for end of life
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
The hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability (MIB7)
NICE has developed a Medtech Innovation Briefing (MIB) on the hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention for treating acute coronary syndromes in adults.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.
Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)
This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
Weight management: lifestyle services for overweight or obese adults (PH53)
This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.
Evidence-based recommendations on NIOX MINO, NIOX VERO and NObreath for measuring the amount of exhaled nitric oxide (FeNO) in the breath to help diagnose
Insertion of a magnetic bead band for faecal incontinence (IPG483)
Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
Psychosis and schizophrenia in adults: prevention and management (CG178)
This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.
This quality standard covers providing and organising cancer services for babies, children and young people (from birth to 24 years, although the upper age limit may vary). It describes high-quality care in priority areas for improvement.
View quality statements for QS55Show all sections
Sections for QS55
- Quality statements
- Quality statement 1: Multidisciplinary teams for young people
- Quality statement 2: Access to clinical trials
- Quality statement 3: Electronic prescribing of chemotherapy
- Quality statement 4: Psychological and social support
- Quality statement 5: Neuro-rehabilitation
- Quality statement 6: Follow-up and monitoring of late effects
- Quality statement 7: Fertility support
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)
Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)
NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system
The NGAL Test for early diagnosis of acute kidney injury (MIB3)
NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .
The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)
NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system
Evidence-based recommendations on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. This involves pulling back the parts of the prostate that are pressing on the urethra so that it's no longer blocked.
Transcranial magnetic stimulation for treating and preventing migraine (IPG477)
Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.
This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.
View quality statements for QS50Show all sections
Sections for QS50
- Quality statements
- Quality statement 1: Participation in meaningful activity
- Quality statement 2: Personal identity
- Quality statement 3: Recognition of mental health conditions
- Quality statement 4: Recognition of sensory impairment
- Quality statement 5: Recognition of physical problems
- Quality statement 6: Access to healthcare services
- Update information
Evidence-based recommendations on phrenic nerve transfer in brachial plexus injury. This involves finding the phrenic nerve, cutting it and joining it to the damaged nerve in the brachial plexus.
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
This quality standard covers diagnosing and managing depression in children and young people (aged 5 to 18). It describes high-quality care in priority areas for improvement.
View quality statements for QS48Show all sections
Sections for QS48
- Quality statements
- Quality statement 1: Confirming and recording a diagnosis
- Quality statement 2: Information appropriate to age
- Quality statement 3: Suspected severe depression and at high risk of suicide
- Quality statement 4: Suspected severe depression without high risk of suicide
- Quality statement 5: Monitoring progress
- Update information
- About this quality standard
Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (IPG461)
Evidence-based recommendations on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. This involves using heat from electrodes to change the tissues in the oesophagus, with the aim of reducing symptoms.
Evidence-based recommendations on translaryngeal tracheostomy (TLT). This involves passing a tube from inside the windpipe to outside the neck to aid breathing.
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion
Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.
Guide to the methods of technology appraisal 2013
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.
View recommendations for IPG446Show all sections
Sections for IPG446
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Antisocial personality disorder: prevention and management (CG77)
This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.
Hepatitis B and C testing: people at risk of infection (PH43)
This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.